KEYTRUDA Pembrolizumab 100mg Injection

DESCRIPTION

KEYTRUDA 100mg (Pembrolizumab) is a prescription drug used to treat a certain type of skin cancer called melanoma and also used to treat a kind of non–small cell lung cancer (NSCLC).

Manufacturer : Merck & Co., Inc.

ADDITIONAL INFORMATION

Strengths available :  100mg

Storage :  Store at temperature between 2°C to 8°C

It is US FDA approved

Dosage :

Recommended Dosage for Melanoma

The recommended dose of KEYTRUDA is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.

Recommended Dosage for NSCLC

The recommended dose of KEYTRUDA is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

​When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA should be administered prior to chemotherapy when given on the same day [see Clinical Studies (14.2)]. See also the Prescribing Information for pemetrexed and carboplatin.

SIDE EFFECTS

Most common side effects areShortness of breath, Diarrhea, Nausea or vomiting, Rapid heart beat, Weight loss or weight gain, Increased sweating, Feeling more hungry or thirsty, Urinating more often than usual, Hair loss, Constipation, Dizziness or fainting

PACK SIZE

Pack of 1 Vial

Reviews

There are no reviews yet.

Be the first to review “KEYTRUDA Pembrolizumab 100mg Injection”

Your email address will not be published. Required fields are marked *